Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers

NCT07542262 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Gastric Cancer

Interventions

DRUG: Low-dose nivolumab
DRUG: Low-dose nivolumab with/without chemotherapy
DRUG: Low-dose nivolumab combined with chemotherapy

Sponsor

Blokhin's Russian Cancer Research Center